Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Frequently asked questions
What sector does Viking Therapeutics Inc (VKTX) operate in?
Viking Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Viking Therapeutics Inc (VKTX) current stock price?
As of the latest data, Viking Therapeutics Inc stock price is $30.11, with a previous close of $28.99. Viking Therapeutics Inc gained $1.12 in the last trading session, representing a 3.86% increase.
What is Viking Therapeutics Inc (VKTX) current market capitalization?
Viking Therapeutics Inc market cap is approximately 3.51 billion.
What is Viking Therapeutics Inc (VKTX) Earnings Per Share (EPS)?
The trailing EPS is -$4.61, and the forward EPS is -$4.32.
What is Viking Therapeutics Inc (VKTX) EBITDA?
Viking Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -127.86 million.
Does Viking Therapeutics Inc (VKTX) pay dividends?
No. Viking Therapeutics Inc does not pay a dividend.
What is Viking Therapeutics Inc (VKTX) beta (volatility) score?
Viking Therapeutics Inc has a beta of 0.685, indicating lower volatility than the overall market.
